Hostname: page-component-7c8c6479df-5xszh Total loading time: 0 Render date: 2024-03-28T10:42:36.651Z Has data issue: false hasContentIssue false

α-Linolenic acid, linoleic acid and heart failure in women

Published online by Cambridge University Press:  15 December 2011

Emily B. Levitan*
Affiliation:
Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, RPHB 230K, 1530 3rd Avenue S, Birmingham, AL35294-0022, USA
Alicja Wolk
Affiliation:
Division of Nutritional Epidemiology, Institute of Environmental Medicine, Karolinska Institute, Stockholm, Sweden
Niclas Håkansson
Affiliation:
Division of Nutritional Epidemiology, Institute of Environmental Medicine, Karolinska Institute, Stockholm, Sweden
Murray A. Mittleman
Affiliation:
Cardiovascular Epidemiology Research Unit, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, MA, USA Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA
*
*Corresponding author: E. B. Levitan, fax +1 205 934 8665, email elevitan@uab.edu
Rights & Permissions [Opens in a new window]

Abstract

α-Linolenic acid (18 : 3n-3) intake and linoleic acid (18 : 2n-6) intake have been associated with lower rates of CHD, though results have not been consistent. The relationship of these fatty acids with incident heart failure (HF) is not well established. We examined the hypothesis that women with higher intakes of 18 : 3n-3 and 18 : 2n-6 would have lower rates of HF hospitalisation and mortality. We measured 18 : 3n-3 and 18 : 2n-6 intake in 36 234 Swedish Mammography Cohort participants aged 48–83 years using FFQ and followed participants through Swedish inpatient and cause-of-death registers from 1 January 1998 until 31 December 2006. Cox models were used to calculate incidence rate ratios (RR) and 95 % CI. Because of multicollinearity, 18 : 3n-3 and 18 : 2n-6 were examined separately. Over 9 years, 596 women were hospitalised and fifty-five died due to HF. In models accounting for age and other covariates, the RR for HF comparing the top quintile of 18 : 3n-3 (median 1·50 g/d) with the bottom quintile (median 0·88 g/d) was 0·91 (95 % CI 0·71, 1·17, Ptrend = 0·41). The RR comparing the top quintile of 18 : 2n-6 (median 7·8 g/d) with the bottom quintile (median 4·6 g/d) was 1·14 (95 % CI 0·88, 1·46, Ptrend = 0·36). We did not find evidence for the interaction of 18 : 3n-3 and 18 : 2n-6 with each other or with long-chain n-3 fatty acids. In conclusion, these data do not support our hypothesis that 18 : 3n-3 and 18 : 2n-6 are associated with HF. However, these results may not be generalisable to populations with higher intakes of 18 : 3n-3.

Type
Full Papers
Copyright
Copyright © The Authors 2011

Heart failure (HF) is an end-stage CVD with a lifetime risk of approximately 20 %(Reference Lloyd-Jones, Adams and Brown1). Although treatment for HF has improved, death rates are still high; mortality is more than 20 % within 1 year of diagnosis(Reference Levy, Kenchaiah and Larson2). In order to reduce the public health impact of HF, prevention strategies are needed(Reference Schocken, Benjamin and Fonarow3). One non-pharmacological target for intervention is diet. However, the relationship of diet with the development of HF is largely unknown, and existing dietary strategies to prevent or ameliorate HF risk factors such as hypertension and diabetes are underutilised(Reference Schocken, Benjamin and Fonarow3).

Supplementation with the long-chain n-3 PUFA EPA and DHA, found primarily in fish, may reduce mortality in patients with myocardial infarction (MI) and HF(4, 5), and dietary intake is associated with lower rates of CVD including sudden death(Reference Albert, Hennekens and O'Donnell6), CHD(Reference Wang, Harris and Chung7) and HF(Reference Mozaffarian, Bryson and Lemaitre8Reference Levitan, Wolk and Mittleman11). The plant-derived n-3 fatty acid α-linolenic acid (18 : 3n-3) is more abundant in the food supply than long-chain n-3 fatty acids, and 18 : 3n-3 can be metabolised into the long-chain n-3 fatty acids, although at a low rate(Reference Brenna12). This rate is even lower in people with a substantial dietary intake of long-chain n-3 fatty acids(Reference Brenna12). A higher intake of 18 : 3n-3 has been associated with a lower rate of CHD in some populations(Reference Campos, Baylin and Willett13Reference Mente, de Koning and Shannon15), but a recent study did not find an association with HF(Reference Belin, Greenland and Martin16). Overall, supplementation with neither 18 : 3n-3 nor long-chain n-3 fatty acids significantly reduced major cardiovascular events in a recent trial in people with a history of MI(Reference Kromhout, Giltay and Geleijnse17). However, among the women in the trial, those who received 18 : 3n-3 had a 27 % lower rate of major cardiovascular events, which approached statistical significance (P = 0·07)(Reference Kromhout, Giltay and Geleijnse17).

The most prevalent PUFA in the food supply is n-6 linoleic acid (18 : 2n-6)(Reference Kris-Etherton, Taylor and Yu-Poth18). 18 : 2n-6 competes with 18 : 3n-3 for elongation enzymes, and the intake of one fatty acid may modify the effect of the other(Reference Brenna12). Because 18 : 2n-6 is a metabolic precursor to inflammatory eicosanoids, there has been concern that too much 18 : 2n-6 or an imbalance in the ratio of n-6:n-3 fatty acids may increase the risk of CVD(Reference Harris, Mozaffarian and Rimm19). However, in studies of human subjects, higher 18 : 2n-6 was not associated with an increase in inflammation(Reference Czernichow, Thomas and Bruckert20). Substituting 18 : 2n-6 for carbohydrate decreases LDL-cholesterol and increases HDL-cholesterol, which is expected to result in lower cardiovascular risk(Reference Mensink, Zock and Kester21). In addition, 18 : 2n-6 consumption has been inversely associated with the rate of CHD in some studies(Reference Mozaffarian, Ascherio and Hu14, Reference Czernichow, Thomas and Bruckert20, Reference Oh, Hu and Manson22), though many studies have found no significant association(Reference Harris, Mozaffarian and Rimm19, Reference Czernichow, Thomas and Bruckert20).

We hypothesised that a higher intake of both 18 : 3n-3 and 18 : 2n-6 would reduce the risk of HF. We examined the associations of 18 : 3n-3 and 18 : 2n-6 with HF hospitalisation and mortality in a population of middle-aged and older women. Because some studies have suggested that the health effects of 18 : 3n-3 may depend on the intake of long-chain n-3 fatty acids and 18 : 2n-6(Reference Brenna12, Reference Mozaffarian, Ascherio and Hu14), we examined whether the associations varied by the intake of other PUFA.

Methods

Participants

The present study included participants in the Swedish Mammography Study. The recruitment process, characteristics of the cohort and study methods have previously been described in detail(Reference Wolk, Larsson and Johansson23). Women born between 1914 and 1948 and living in Västmanland and Uppsala counties in central Sweden received a questionnaire between 1 March 1987 and 14 December 1990. Of the 90 303 women identified in the population register, 66 651 (74 %) returned a completed questionnaire. In September 1997, a second questionnaire was sent to 56 030 participants who were still alive and residing in the study area; 39 227 (70 %) returned a questionnaire. Because information on cardiovascular risk factors such as cigarette smoking was collected on the second questionnaire, only women who completed the 1997 questionnaire were included in the present study. The present study is based on information from the 1997 questionnaire.

Participants who did not provide or provided incorrect national identification numbers, who reported implausible energy intakes (>3 standard deviations from the natural logarithm-transformed mean), who had a previous diagnosis of cancer (other than non-melanoma skin cancer) or HF were excluded (n 1126). Because patients with diabetes or MI are often counselled to alter their diets and diabetes and MI are risk factors for HF, only women with no baseline history of MI or diabetes were included (n 36 234). History of HF and MI was determined through record linkage to the Swedish inpatient register, and diabetes was determined using self-report and record linkage. The study was conducted according to the guidelines laid down in the Declaration of Helsinki and all procedures involving human subjects/patients were approved by the Regional Ethical Review Board at Karolinska Institute, Stockholm, Sweden. Completion and return of the self-administered questionnaire was assumed to imply consent.

Diet assessment

Self-administered food-frequency items on the questionnaires asked participants to report usual frequency of consumption of ninety-six items over the previous year. For foods and beverages such as milk, coffee, cheese and bread that are commonly eaten in Sweden, participants reported their consumption in servings per d or per week. For other foods and beverages, there were eight predefined responses ranging from never to ≥ 3 times/d. For each food and beverage, total consumption was calculated by multiplying the frequency of consumption by age-specific portion sizes which were determined using weighed dietary records. Nutrient values were calculated by multiplying the food or beverage intake by the nutrient composition obtained from the Swedish National Food Administration(Reference Bergström, Kylberg and Hagman24) and summing over foods and beverages. Nutrient intakes were adjusted for energy using the residual method(Reference Willett25). Among 239 women included in a study of the questionnaire performance, correlations between FFQ and adipose tissue biopsies were 0·34 for 18 : 3n-3 and 0·36 for 18 : 2n-6 (A Wolk, unpublished results).

Heart failure follow-up

Participants were followed from 1 January 1998 until 31 December 2006 through record linkage to the Swedish inpatient and cause-of-death registers. The inpatient register captures more than 99 % of inpatient care in Sweden. HF events were defined as hospitalisations for or deaths from HF identified by codes 428 (International Classification of Disease-9), I50 or I11·0 (International Classification of Disease-10) listed as the primary diagnosis. In a previous study, 95 % of people with these codes as the primary diagnosis had confirmed HF on medical record review using the European Society of Cardiology criteria(Reference Ingelsson, Arnlov and Sundstrom26). We included the first HF event recorded in the registers for each individual.

Statistical analysis

Because some participants were missing data on weight or height to calculate BMI (1·7 %) and physical activity (22·4 %), we used Markov chain Monte Carlo multiple imputation to simulate five complete datasets. Statistical analyses were performed in each of the datasets separately, and the results were then averaged and the CI and P values calculated accounting for uncertainty in the imputed estimates(Reference Schafer27).

We computed means and percentages of demographic, behavioural and health covariates by quintiles of intake of 18 : 3n-3 and 18 : 2n-6. To estimate the incidence rate ratios (RR) associated with 18 : 3n-3 and 18 : 2n-6, we used Cox proportional hazards models that accounted for age by allowing the baseline hazard to vary(Reference Collett28). We adjusted for BMI (linear), physical activity (linear), energy intake (linear), alcohol consumption (linear), fibre consumption (linear), Na consumption (linear), education (less than high school, high school or university), family history of myocardial infarction at < 60 years (yes or no), cigarette smoking (current, past or never), living alone (yes or no), postmenopausal hormone use (yes or no), self-reported history of hypertension (yes or no) and self-reported history of high cholesterol (yes or no). Nutrient replacement models that additionally adjusted for all but one of the macronutrients demonstrated multicollinearity (highest condition index = 378), suggesting that results of the models could be severely biased. We tested for linear trend by entering the median 18 : 3n-3 or 18 : 2n-6 in each quintile as a continuous variable. Assuming a HF rate of two cases per 1000 person-years based on preliminary data and setting the significance level to 0·05, we estimated that there would be at least 80 % power to detect a RR of 0·72 or lower and 1·47 or higher comparing top with bottom quintiles using the Schoenfeld & Richter approach(Reference Schoenfeld and Richter29).

We examined the associations with 18 : 3n-3 and 18 : 2n-6 modelled as continuous exposures, expressed as percentage of total fat. We explored the effect of measurement error in 18 : 3n-3 and 18 : 2n-6 using the regression calibration approach(Reference Willett25) and additional data from the 239 women with fat biopsies. We examined whether the association between 18 : 3n-3 and the incidence of HF hospitalisation or mortality varied by long-chain n-3 intake above or below the median (0·30 g/d) and by 18 : 2n-6 above or below the median (5·9 g/d). We tested for interaction by including the product of the median in each quintile for 18 : 3n-3 and an indicator for being above the median intake of long-chain n-3 or 18 : 2n-6 in the models. Similarly, we examined whether the relationship between 18 : 2n-6 intake and the incidence of HF hospitalisation or mortality varied by long-chain n-3 intake and 18 : 3n-3 intake above or below the median. We examined the relationship between the major food sources of variability in 18 : 3n-3 and 18 : 2n-6 intake and the incidence of HF hospitalisation or mortality. Because symptoms of HF occurring before hospitalisation or death may influence dietary behaviour, we performed a sensitivity analysis excluding cases occurring during the first 2 years of follow-up. We tested for violations of the proportional hazards assumption by entering the product of 18 : 3n-3 or 18 : 2n-6 and the natural logarithm of time in the model. The proportional hazards assumption did not appear to be violated.

Statistical analyses were performed using SAS version 9.1. A two-sided P value < 0·05 was considered statistically significant.

Results

Over 9 years of follow-up, 651 of the 36 234 women were hospitalised for HF (n 596) or died of HF (n 55). Intake of 18 : 3n-3 and 18 : 2n-6 was highly correlated (r 0·79). On average, 2 % of fat consumed was 18 : 3n-3 and 10 % was 18 : 2n-6. Compared with women in the lowest quintile of 18 : 3n-3 intake, women in the highest quintile were more likely to be current smokers (Table 1). On average, they consumed more fibre, Na, saturated fat and long-chain n-3 fatty acids, and less alcohol, protein and carbohydrate. Foods that contributed to the variability in 18 : 3n-3 intake included soya products, mayonnaise and salad dressing; however, the absolute intake of these foods was low. Compared with women in the lowest quintile of 18 : 2n-6 intake, women in the highest quintile were on average younger, more likely to be current smokers, more likely to have a university education, less likely to live alone and less likely to self-report a history of hypertension or high cholesterol (Table 2). The mean intake of alcohol, fibre, Na and long-chain n-3 was higher and the mean intake of protein and carbohydrate was lower in women in the top quintile of 18 : 2n-6 intake compared with the bottom quintile. Foods that accounted for variability in 18 : 2n-6 intake included soya products, nuts, mayonnaise and salad dressing.

Table 1 Characteristics of 36 234 women aged 48–83 years by α-linolenic acid consumption

(Mean values and standard deviations; percentages)

Table 2 Characteristics of 36 234 women aged 48–83 years by linoleic acid consumption

(Mean values and standard deviations; percentages)

We did not find a significant association between 18 : 3n-3 intake and the incidence of HF hospitalisation or mortality in models accounting for age and other covariates (Table 3). The relationships did not vary by intake of long-chain n-3 (P for interaction = 0·29) or by intake of 18 : 2n-6 (P for interaction = 0·81). The RR for a 1 standard deviation difference in 18 : 3n-3 as the percentage of total fat (0·4 % of total fat) was 1·00 (95 % CI 0·91, 1·10) before adjustment for measurement error and 1·01 (95 % CI 0·55, 1·85) after adjustment for measurement error.

Table 3 α-Linolenic acid, linolenic acid and incidence of heart failure hospitalisation or mortality among 36 234 women aged 48–83 years

RR, rate ratio.

* Cox proportional hazards model accounting for age.

Cox proportional hazards model accounting for age and adjusted for BMI, physical activity, energy intake, alcohol consumption, fibre consumption, Na consumption, education, family history of myocardial infarction at < 60 years, cigarette smoking, living alone, postmenopausal hormone use, self-reported history of hypertension, and self-reported history of high cholesterol.

18 : 2n-6 was also not significantly associated with the incidence of HF. We did not find evidence that the relationship between 18 : 2n-6 and HF varied by long-chain n-3 intake (P for interaction = 0·54). The RR for a 1 standard deviation difference in 18 : 2n-6 as the percentage of total fat (2·7 % of total fat) was 1·04 (95 % CI 0·95, 1·14) before adjustment for measurement error and 1·20 (95 % CI 0·54, 2·66) after adjustment for measurement error.

In nutrient replacement models, 18 : 3n-3 was not significantly associated with HF, but the RR for the top quintile compared with the bottom quintile of 18 : 2n-6 was 1·57 (95 % CI 1·06, 2·34). This estimate was greatly attenuated when either carbohydrate or saturated fat was removed from the model, and there was strong evidence of model-fitting problems due to multicollinearity. We did not find significant associations between the consumption of soya products, nuts, mayonnaise or salad dressing one or more times per week and the incidence of HF events (Table 4). Results were not materially different when the first 2 years of follow-up were excluded.

Table 4 Intake of high α-linolenic acid or linoleic acid foods and incidence of heart failure hospitalisation or mortality among 36 234 women aged 48–83 years

RR, rate ratio.

* Cox proportional hazards model accounting for age and adjusted for BMI, physical activity, energy intake, alcohol consumption, fibre consumption, Na consumption, education, family history of myocardial infarction at < 60 years, cigarette smoking, living alone, postmenopausal hormone use, self-reported history of hypertension, and self-reported history of high cholesterol.

Discussion

In this population of middle-aged and older women, there was no significant association of 18 : 3n-3 or 18 : 2n-6 or their major foods sources with the incidence of HF hospitalisation or mortality. We did not find evidence that the associations differed by intake of other PUFA. We had hypothesised that both 18 : 3n-3 and 18 : 2n-6 would have inverse associations with the incidence of HF. However, intake of 18 : 3n-3 was relatively low; an association between 18 : 3n-3 and HF may be evident at higher levels of intake than observed in the Swedish Mammography Cohort. The present results are consistent with a recent large study of women from the USA, which also failed to find an association between 18 : 3n-3 and HF(Reference Belin, Greenland and Martin16). In addition, we were not able to examine independent effects of 18 : 3n-3 and 18 : 2n-6 because of the correlation between them.

There is strong evidence from numerous randomised, controlled feeding studies that PUFA reduced LDL-cholesterol and increased HDL-cholesterol when substituted for carbohydrate(Reference Mensink, Zock and Kester21). However, dyslipidaemia is a minor risk factor for HF(Reference Schocken, Benjamin and Fonarow3). Dyslipidaemia can cause CHD, a major risk factor for HF(Reference Schocken, Benjamin and Fonarow3). Intake of both 18 : 3n-3 and 18 : 2n-6 has been inversely associated with incident CHD, but the results have not been consistent and are not conclusive(Reference Campos, Baylin and Willett13Reference Mente, de Koning and Shannon15, Reference Czernichow, Thomas and Bruckert20). In the present study, we excluded women with prevalent MI, and follow-up may not have been long enough to complete a proposed pathway from low 18 : 3n-3 and 18 : 2n-6 intake to dyslipidaemia to MI to HF.

18 : 3n-3 can be converted into long-chain n-3 fatty acids that have a number of beneficial effects, including potentially reducing post-MI mortality and mortality among people with HF(4, 5, Reference Kromhout, Giltay and Geleijnse17), decreasing propensity to arrhythmia in many settings(Reference Reiffel and McDonald30), and, at high doses, reducing TAG concentrations(Reference Harris, Ginsberg and Arunakul31). Our previous work and work of others suggested that moderate intake of long-chain n-3 fatty acids may decrease the risk of HF(Reference Mozaffarian, Bryson and Lemaitre8Reference Levitan, Wolk and Mittleman11). In one study, there was an inverse association between dark fish, a major dietary source of long-chain n-3 fatty acids, and HF but no association with long-chain n-3 fatty acids themselves(Reference Belin, Greenland and Martin16). Conversion of 18 : 3n-3 to long-chain n-3 fatty acids is inefficient and seems to be affected by the intake of 18 : 2n-6 and long-chain n-3 as well as variations in fatty acid desaturase genes(Reference Brenna12, Reference Glaser, Heinrich and Koletzko32). Both 18 : 3n-3 and 18 : 2n-6 are essential fatty acids for humans, which must be obtained from the diet. The present study examined the range of intake reported by a relatively healthy population rather than frank deficiencies in the nutrients. We were not able to examine higher intakes that are consumed in some populations or are possible through supplementation. It is possible that an effect of 18 : 3n-3 would be evident in a population with a higher intake of 18 : 3n-3 or a lower intake of long-chain n-3 fatty acids and 18 : 2n-6. We attempted to address this issue by looking for interactions between 18 : 3n-3 and the other fatty acids; however, we were limited to only examining patterns of consumption that exist in this population.

18 : 3n-3 and 18 : 2n-6 are consumed together in foods and are highly correlated. It is difficult to separate out effects of the two types of polyunsaturated fat, which limits the conclusions we can draw about their biological action. In this population, soya products, mayonnaise and salad dressing contributed importantly to the variability in both 18 : 3n-3 and 18 : 2n-6. Nutrient replacement models, which are often used when examining the relationships of macronutrients with disease, were not reliable in the present study because of multicollinearity. We therefore could not determine the independent effects of 18 : 3n-3 and 18 : 2n-6. Feeding studies that directly manipulate specific fatty acids would be able to determine specific effects of 18 : 3n-3 and 18 : 2n-6. In order to realise any public health benefit from differentially altering 18 : 3n-3 and 18 : 2n-6 intake, changes to the food supply to provide these fats independent of one another would be necessary. We expect some misclassification of 18 : 3n-3 and 18 : 2n-6 intake because dietary intake was measured using questionnaires. This misclassification limits our ability to detect moderately sized effects of nutrients. We used regression calibration to try to take the measurement errors into account; however, this technique relies on a number of strong assumptions and does not fully account for the bias towards the null that results from random errors(Reference Willett25). HF is a clinical syndrome with variable presentation and aetiology, and we did not have information on HF subtype. Although Swedish inpatient and cause-of-death registers are almost complete and the accuracy of HF diagnosis has been shown to be high(Reference Ingelsson, Arnlov and Sundstrom26), the registers only captured cases that result in hospitalisation or death. Therefore, the present results may not be generalisable to HF treated on an outpatient basis. While the present study had sufficient power to detect a 30 % decrease in the rate of HF associated with the fatty acids, we did not have power to reliably detect more subtle associations. Finally, as with all observational studies, we were not able to rule out bias due to residual or unmeasured confounding. In particular, it can be difficult to distinguish between the effect of nutrients and the effect of the foods that supply those nutrients.

In summary, we did not find evidence for an association between 18 : 3n-3 or 18 : 2n-6 intake and the incidence of HF hospitalisation and mortality in this population of women from central Sweden. The present results may not be generalisable to populations with a higher intake of 18 : 3n-3 than observed in this population. Further work with other populations and other study designs is needed to determine whether a high intake of 18 : 3n-3 can prevent HF and to tease out independent effects of 18 : 3n-3 and 18 : 2n-6.

Acknowledgements

This study was supported by grants from the Swedish Research Council/Committee for Infrastructure, Swedish Research Council/Committee for Medicine, and the Swedish Foundation for International Cooperation in Research and Higher Education. None of the authors has any conflicts of interest related to this work. The contribution of each author is as follows: E. B. L., A. W., N. H. and M. A. M. designed the study; A. W. and N. H. collected the data; E. B. L. and N. H. performed the analysis; E. B. L. wrote the manuscript; A. W., N. H. and M. A. M. revised the manuscript.

References

1Lloyd-Jones, D, Adams, RJ, Brown, TM, et al. (2010) Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation 121, e46e215.Google ScholarPubMed
2Levy, D, Kenchaiah, S, Larson, MG, et al. (2002) Long-term trends in the incidence of and survival with heart failure. N Engl J Med 347, 13971402.CrossRefGoogle ScholarPubMed
3Schocken, DD, Benjamin, EJ, Fonarow, GC, et al. (2008) Prevention of heart failure: a scientific statement from the American Heart Association Councils on Epidemiology and Prevention, Clinical Cardiology, Cardiovascular Nursing, and High Blood Pressure Research; Quality of Care and Outcomes Research Interdisciplinary Working Group; and Functional Genomics and Translational Biology Interdisciplinary Working Group. Circulation 117, 25442565.CrossRefGoogle Scholar
4Anonymous (1999) Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet 354, 447455.CrossRefGoogle Scholar
5GISSI-HF Investigators (2008) Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 372, 12231230.CrossRefGoogle Scholar
6Albert, CM, Hennekens, CH, O'Donnell, CJ, et al. (1998) Fish consumption and risk of sudden cardiac death. JAMA 279, 2328.CrossRefGoogle ScholarPubMed
7Wang, C, Harris, WS, Chung, M, et al. (2006) n-3 Fatty acids from fish or fish-oil supplements, but not alpha-linolenic acid, benefit cardiovascular disease outcomes in primary- and secondary-prevention studies: a systematic review. Am J Clin Nutr 84, 517.CrossRefGoogle Scholar
8Mozaffarian, D, Bryson, CL, Lemaitre, RN, et al. (2005) Fish intake and risk of incident heart failure. J Am Coll Cardiol 45, 20152021.CrossRefGoogle ScholarPubMed
9Yamagishi, K, Iso, H, Date, C, et al. (2008) Fish, omega-3 polyunsaturated fatty acids, and mortality from cardiovascular diseases in a nationwide community-based cohort of Japanese men and women the JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk) Study. J Am Coll Cardiol 52, 988996.CrossRefGoogle Scholar
10Levitan, EB, Wolk, A & Mittleman, MA (2009) Fish consumption, marine omega-3 fatty acids, and incidence of heart failure: a population-based prospective study of middle-aged and elderly men. Eur Heart J 30, 14951500.CrossRefGoogle ScholarPubMed
11Levitan, EB, Wolk, A & Mittleman, MA (2010) Fatty fish, marine omega-3 fatty acids and incidence of heart failure. Eur J Clin Nutr 64, 587594.CrossRefGoogle ScholarPubMed
12Brenna, JT (2002) Efficiency of conversion of alpha-linolenic acid to long chain n-3 fatty acids in man. Curr Opin Clin Nutr Metab Care 5, 127132.CrossRefGoogle Scholar
13Campos, H, Baylin, A & Willett, WC (2008) Alpha-linolenic acid and risk of nonfatal acute myocardial infarction. Circulation 118, 339345.CrossRefGoogle ScholarPubMed
14Mozaffarian, D, Ascherio, A, Hu, FB, et al. (2005) Interplay between different polyunsaturated fatty acids and risk of coronary heart disease in men. Circulation 111, 157164.CrossRefGoogle ScholarPubMed
15Mente, A, de Koning, L, Shannon, HS, et al. (2009) A systematic review of the evidence supporting a causal link between dietary factors and coronary heart disease. Arch Intern Med 169, 659669.CrossRefGoogle ScholarPubMed
16Belin, RJ, Greenland, P, Martin, L, et al. (2011) Fish intake and the risk of incident heart failure: the Women's Health Initiative. Circ Heart Fail 4, 404413.CrossRefGoogle ScholarPubMed
17Kromhout, D, Giltay, EJ & Geleijnse, JM (2010) n-3 Fatty acids and cardiovascular events after myocardial infarction. N Engl J Med 363, 20152026.CrossRefGoogle ScholarPubMed
18Kris-Etherton, PM, Taylor, DS, Yu-Poth, S, et al. (2000) Polyunsaturated fatty acids in the food chain in the United States. Am J Clin Nutr 71, 179S188S.CrossRefGoogle ScholarPubMed
19Harris, WS, Mozaffarian, D, Rimm, E, et al. (2009) Omega-6 fatty acids and risk for cardiovascular disease: a science advisory from the American Heart Association Nutrition Subcommittee of the Council on Nutrition, Physical Activity, and Metabolism; Council on Cardiovascular Nursing; and Council on Epidemiology and Prevention. Circulation 119, 902907.CrossRefGoogle Scholar
20Czernichow, S, Thomas, D & Bruckert, E (2010) n-6 Fatty acids and cardiovascular health: a review of the evidence for dietary intake recommendations. Br J Nutr 104, 788796.CrossRefGoogle Scholar
21Mensink, RP, Zock, PL, Kester, AD, et al. (2003) Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials. Am J Clin Nutr 77, 11461155.CrossRefGoogle ScholarPubMed
22Oh, K, Hu, FB, Manson, JE, et al. (2005) Dietary fat intake and risk of coronary heart disease in women: 20 years of follow-up of the Nurses' Health Study. Am J Epidemiol 161, 672679.CrossRefGoogle ScholarPubMed
23Wolk, A, Larsson, SC, Johansson, JE, et al. (2006) Long-term fatty fish consumption and renal cell carcinoma incidence in women. JAMA 296, 13711376.CrossRefGoogle ScholarPubMed
24Bergström, L, Kylberg, E, Hagman, U, et al. (1991) The food composition database KOST: the National Administration's information system for nutritive values of food. Var Foda 43, 439447.Google Scholar
25Willett, WC (1998) Nutritional Epidemiology, 2nd ed.New York, NY: Oxford University Press.CrossRefGoogle Scholar
26Ingelsson, E, Arnlov, J, Sundstrom, J, et al. (2005) The validity of a diagnosis of heart failure in a hospital discharge register. Eur J Heart Fail 7, 787791.CrossRefGoogle Scholar
27Schafer, JL (1997) Analysis of Incomplete Multivariate Data. Boca Raton: CRC Press.CrossRefGoogle Scholar
28Collett, D (2003) Modelling Survival Data in Medical Research, 2nd ed.Boca Raton: Chapman & Hall/CRC.Google Scholar
29Schoenfeld, DA & Richter, JR (1982) Nomograms for calculating the number of patients needed for a clinical trial with survival as an endpoint. Biometrics 38, 163170.CrossRefGoogle ScholarPubMed
30Reiffel, JA & McDonald, A (2006) Antiarrhythmic effects of omega-3 fatty acids. Am J Cardiol 98, 50i60i.CrossRefGoogle ScholarPubMed
31Harris, WS, Ginsberg, HN, Arunakul, N, et al. (1997) Safety and efficacy of Omacor in severe hypertriglyceridemia. J Cardiovasc Risk 4, 385391.CrossRefGoogle ScholarPubMed
32Glaser, C, Heinrich, J & Koletzko, B (2010) Role of FADS1 and FADS2 polymorphisms in polyunsaturated fatty acid metabolism. Metabolism 59, 993999.CrossRefGoogle ScholarPubMed
Figure 0

Table 1 Characteristics of 36 234 women aged 48–83 years by α-linolenic acid consumption(Mean values and standard deviations; percentages)

Figure 1

Table 2 Characteristics of 36 234 women aged 48–83 years by linoleic acid consumption(Mean values and standard deviations; percentages)

Figure 2

Table 3 α-Linolenic acid, linolenic acid and incidence of heart failure hospitalisation or mortality among 36 234 women aged 48–83 years

Figure 3

Table 4 Intake of high α-linolenic acid or linoleic acid foods and incidence of heart failure hospitalisation or mortality among 36 234 women aged 48–83 years